There is an evident detrimental effect of iron excess or bone homeostasis which can manifest itself in different ways, including low BMD, osteoporosis or osteopenia as well as altered microarchitecture and biomechanics. These conditions increase the incidence of pathologic fractures in patients suffering from diverse types of iron overload. The effect of iron deficiency on bone health is less clear, but some studies suggest that this condition is also associated with weakened bones, highlighting that balanced bone homeostasis requires optimal—not too low, not too high—iron levels.
I haven't had time to look at this closely, but in a scan no numbers for guidance jump out.
For women after menopause it states:
Menopause is a complex process, characterized by hormonal alterations, such as a marked decline of estrogen level. Interestingly, studies revealed a negative correlation between estrogen and serum ferritin levels, and mounting evidence suggests that the 2–3-fold increase in iron/ferritin levels in postmenopausal women influences their health [75,76,77]. About one-third of post-menopausal women suffer from osteoporosis and subsequent osteoporotic fractures [78,79,80]. Recent studies addressed whether increased iron stores effect bone health in women following menopause. They showed that the rate of annual bone loss correlates to plasma ferritin levels [iron storage] highlighting that elevated total body iron stores is an independent risk factor for enhanced bone loss in postmenopausal women [81,82].
Interestingly, a recent study revealed that the prevalence of low BMD is lower in elderly (>60 years) people with high serum ferritin levels (<200 ng/mL). This finding warrants the need of further studies to clarify the association between serum ferritin concentrations and BMD in different populations .
Darn, wish these findings weren't contradictory.
I followed the protocol on this study for a couple years, give or take, and my bone health worsened.
Melatonin-micronutrients Osteopenia Treatment Study (MOTS): A translational study assessing melatonin, strontium (citrate), vitamin D3 and vitamin K2 (MK7) on bone density, bone marker turnover and health related quality of life in postmenopausal osteopenia[/url]
These findings provide both clinical and mechanistic support for the use of MSDK for the prevention or treatment of osteopenia, osteoporosis or other bone-related diseases.
Interestingly, it doesn't appear to have a focus on increasing alkalinity, or specifically potassium, so maybe it was working but just not well enough without that.
Who knows but I appreciate you giving me a new avenue to consider.